TSI Group Co (603262.SS) Stock Price

TSI Group Co., Ltd. generates revenue through the research, development, and manufacturing of dietary nutritional supplements, primarily selling nutritional raw materials like β-hydroxy β-methyl butyrate (HMB), glucosamine, and chondroitin sulfate, as well as finished products such as tablets and hard capsules. The company markets its branded products under myHMB and GlucosaGreen, targeting both domestic and international consumers through its global distribution channels. Its main customers include health supplement retailers, pharmaceutical companies, and wellness brands that purchase raw materials and finished formulations for their own product lines. TSI Group's product portfolio focuses on high-demand nutritional ingredients, with HMB, glucosamine, and chondroitin sulfate serving as core offerings for sports nutrition and joint health applications. The myHMB brand specifically emphasizes muscle support, while GlucosaGreen targets joint care, aligning with consumer trends in functional nutrition. The company's domestic market presence complements its overseas sales, leveraging its Shanghai headquarters for global operations. The firm's revenue streams are driven by B2B transactions with manufacturers and retailers, as well as direct sales of branded supplements to end consumers in key markets. By maintaining a dual focus on raw material supply and branded consumer products, TSI Group captures value across the nutritional supplement supply chain, from ingredient sourcing to final product delivery.